Since its founding in 1992, Alexion has given hope to people who had none and shined a light on those who felt isolated and alone. But we know that fighting rare diseases takes so much more than hope. It requires persistence, dedication, and a relentless pursuit of the highest levels of medical innovation. At Alexion, our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives are at stake. Alexion has 3,000 passionate and dedicated employees serving patients in 50 countries around the world.

For more information, contact Steve Meyers at steve.myers-consultant@alexion.com.

Arvinas is a clinical-stage biopharmaceutical company focused on developing new small molecules ‒ known as PROTAC® (PROteolysis Targeting Chimera) protein degraders ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. Our proprietary PROTAC®-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.

For more information, contact Steve Weiss at steve.weiss@arvinas.com.

BioCT is the bioscience industry voice for the state of Connecticut. BioCT is dedicated to growing the vibrant bioscience ecosystem in Connecticut by supporting innovation, collaboration, networking, education, talent engagement and advocacy. We bring together companies, institutions, entrepreneurs, investors, government, service providers, and other passionate, dedicated people, to build a thriving community to improve patients’ lives and public health, while driving economic growth.

For more information, contact Kelley Gipson at kgipson@bioct.org.

BioHaven is a clinical-stage biopharmaceutical company and their portfolio is comprised of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders. In May 2019, they raised $168 million in IPO.

For more information, contact Kari Soderstrom at Kari.Soderstrom@biohavenpharma.com.

Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.

For more information, contact Sophia Salih at sophia.salih@boehringer-ingelheim.com.

Founded in 1929, the Jackson Laboratory is an independent, 501(c)3 nonprofit biomedical research institution. It employs more than 2,200 staff, and its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. JAX researchers combine extensive experience in mammalian genetics and human genomics to shape a unique and integrated approach to personalized medicine. Scientists work collaboratively across disciplines to interrogate disease from all angles, leveraging diverse expertise in cancer, immunology (including diabetes), neurogenetics (including Alzheimer’s disease), life-cycle biology (including development, stem cells, aging and regenerative medicine), the microbiome and computational biology.

For more information, contact Miriam Ortiz at miriam.ortiz@jax.org.

Finding top talent is a key challenge for company executives in 2020. Yale's Office of Career Strategy (OCS) employer relations staff are available to help you build a recruiting strategy that will attract highly skilled Yale students across a diverse array of disciplines. Employers may post full-time and internship opportunities on Yale Career Link. Individual employers may host student engagement events on-campus, or remotely, and participate in one of 10+ industry networking events during the Fall and Spring terms.

For more information about recruiting options, please contact Employer Relations 203-432-0800.

Pfizer careers are like no other. In our culture of individual ownership, we believe in our ability to improve future healthcare, and potential to transform millions of lives. We’re looking for new talent to join our global community, to unearth new innovative therapies that make the world a healthier place.

For more information, contact Danielle Maciag at Danielle.Maciag@pfizer.com.

Thetis is a biopharmaceutical company developing potential first-in-class, non-immunosuppressive therapies for gastrointestinal inflammatory diseases. Founded by ex-Pfizer R&D executives and healthcare entrepreneurs, Thetis has a pipeline of drug candidates that offer a novel therapeutic approach to resolve inflammation without suppressing compromising immune function. Thetis is based in Branford, CT and is funded by Connecticut Innovations and leading research institutions, including National Institutes of Health, the Crohn’s and Colitis Foundation, and the Kenneth Rainin Foundation.

For more information, contact Aaron Mathias at amathias@thetispharma.com.